Do not give yourself extra medication or double your next dose unless you are told to do so
Check LegitScript certification status and review any recent FDA communications regarding compounded GLP-1 products
It is currently available in both subcutaneous and oral formulations.4 Furthermore, the impact of high doses of semaglutide on weight loss was explored in adults with overweight or obesity in the STEP programme.5 Recently, the cardiovascular benefit of high doses of semaglutide was also observed in patients with overweight or obesity at high cardiovascular risk but without T2DM.6 Despite the proven cardiovascular benefit of semaglutide, certain safety concerns still linger
Here we report the results of a clinical study investigating the GCGR and GLP1R occupancy of SAR425899 in individuals with T2D as assessed by repeated PET imaging
In the diabetes TRIUMPH-2 trial, reported side effects included: Diarrhea (around 27 to 34 percent of participants, depending on the dose) Nausea (14 to 28 percent) Constipation (14 to 17 percent) Decreased appetite (6 to 17 percent) Vomiting (6 to 16 percent) In the TRIUMPH-3 trial for adults with severe obesity and heart disease, participants reported: Diarrhea (around 24 to 30 percent of participants, depending on the dose) Nausea (22 percent) Constipation (16 to 18 percent) Decreased appetite (14 to 15 percent) Hyperglycemia, or high blood sugar (3 to 4 percent) The high rates of diarrhea surprised Ali
